

November 22, 2018

MEXICO CANNABIS UPDATE

Mexico issues first authorizations for cannabis products.



The Secretary of Health, through the Federal Commission for the Protection of Sanitary Risks (“COFEPRIS”) announced yesterday the authorization for the first 38 products with cannabis and its derivatives, with no THC or psycho-active effects, to enter the Mexican market within the next five weeks.

As mentioned on our previous update, on October 30, 2018, COFEPRIS issued the Guidelines for the Sanitary Control of Cannabis and its Derivatives (*Lineamientos en Materia de Control Sanitario de la Cannabis y Derivados de la Misma*). Such guidelines set forth the agency’s criteria to be used in the evaluation and resolution of the applications filed to authorize medical and scientific use of cannabis and its pharmacological derivatives, as well as the commercialization, exportation and importation of cannabis products with 1% or less THC content for industrial use. Since that date, COFEPRIS received 51 applications, out of which 38 fully met the requirements.

The authorized products are 21 supplements, 9 for cosmetic use, 6 edible/beverage products and 2 as raw material. Authorized supplements are intended for epilepsy, arthritis, stress and anxiety treatment. Among these products are also relaxants, analgesics and sleep disorders as well as creams and balsams.

The authorizations were obtained by 7 companies, out of which 2 have U.S. equity, and one from Spain.

If you’re interested in learning more details about the authorized products, or have any comments or questions, feel free to email me at larmendariz@caamlegal.mx.

Luis Armendariz

<https://www.linkedin.com/in/luisarmendariz/>